Navigation Links
CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million
Date:5/22/2008

BRANFORD, Conn., May 22 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today the completion of a series of privately negotiated transactions in which the Company sold the 5,000,000 shares of TopoTarget common stock issued to the Company as partial payment for the sale of CuraGen's ownership in belinostat. After expenses, CuraGen will receive approximately $12 million in cash.

"We are pleased to announce the planned, orderly liquidation of our position in TopoTarget stock. These sales, when added to the up-front cash payment we received from TopoTarget on April 22, 2008, bring the total cash realized by CuraGen to approximately $38 million," stated Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "We also retain further potential upside related to belinostat consisting of up to $6 million in potential milestone payments on future net sales and sublicenses of belinostat."

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a clinical-stage biopharmaceutical company developing promising approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's potential economic benefits from future net sales and sublicense of belinostat may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the period ended March 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CuraGen Contacts:

Sean Cassidy

Vice President and Chief Financial Officer

scassidy@curagen.com

Glenn Schulman, Pharm.D.

Director Medical Communications

gschulman@curagen.com

(888) 436-6642

CRGN-F


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CuraGen Reports First Quarter 2008 Financial Results
2. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
3. CuraGen Reports Third Quarter 2007 Financial Results
4. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Actifirm Sells Out in First Hour Appearance on QVC
6. Blackstone Sells Gerresheimer Stake
7. Isolagen, Inc. Sells Switzerland Facility
8. On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group
9. Medifast Franchise Systems Sells First Territory in Baltimore
10. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
11. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 2016 , ... Qualitative research, which is primarily based on ... of the program, policy or intervention being studied. Both quantitative and qualitative research ... In a new brief released today, Reading Qualitative Educational Policy Research, William Mathis ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provide the playing surface for the 2016 NCAA Men’s National Collegiate ... for the men’s volleyball championship to be held May 5-7 at Pennsylvania State ...
(Date:5/4/2016)... ... May 04, 2016 , ... Level 10 Head Over Heels Athletic ... to the University of Arizona for the fall of 2019. , After a ... Brovedani’s commitment to the GymCats came from her connection with the coaching staff and ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... ... 04, 2016 , ... A new collaboration will give more researchers access to ... (DCRI) and analytics leader SAS will provide researchers worldwide with data management and analytics ... Health System. , The DCRI and SAS share the goal of greater transparency ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... ACME Markets, Delaware ... Delaware County Councilman Dave White announced ... ACME pharmacies across Delaware County ... Prevention (CDC), naloxone has saved 26,463 lives nationwide over the past ... Delaware County were authorized to administer naloxone to overdose ...
(Date:5/3/2016)... FLINT, Mich. , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today ... The company released a video of two patients who tell their personal story and encourage ... hepatitis.   Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
Breaking Medicine Technology: